GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

GSK will acquire the liver disease drug efimosfermin from Boston Pharmaceuticals in a deal worth up to $2 billion, The Wall Street Journal reported May 14. The agreement includes a $1.2 billion ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

Loss-making Burberry today led the FTSE 250 index after better-than-expected results fired up hopes that the “best days are ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...

GSK has reported positive outcomes from the Phase III GLISTEN trial of linerixibat for cholestatic pruritus (itch) and PBC.

US President Donald Trump today hailed a 'great' trade deal that will "open up" the UK. And it will. Like an oyster.

MANILA, Philippines — GSK plc (LSE/NYSE: GSK) has today released global survey data showing that over half (52%) of people aged 50-60 feel younger than their age—and nearly a fifth (19% ...